




RealRate

PHARMACEUTICAL 2023

Aridis Pharmaceuticals Inc
Rank 437 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Aridis Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aridis Pharmaceuticals Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 5.4% points. The greatest weakness of Aridis Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 163% points.

The company's Economic Capital Ratio, given in the ranking table, is 68%, being 176% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	11,626
Cost of Goods Sold	0
Intangible Assets	17
Liabilities, Current	36,898
Liabilities, Non-Current	5,528
Other Assets	2,322
Other Compr. Net Income	5,051
Other Expenses	350
Other Liabilities	-3,499
Other Net Income	-121
Other Revenues	3,184
Property and Equipment	730
Research and Development	25,923
Selling, General and Administrative Expense	7,161

Output Variable	Value in 1000 USD
Assets	14,695
Liabilities	38,927
Expenses	33,434
Revenues	3,184
Stockholders Equity	-24,232
Net Income	-30,371
Comprehensive Net Income	-27,846
BaseVar	47,706
ECR before LimitedLiability	-301%
Economic Capital Ratio	68%